Somatostatin receptor type 2 expression in Merkel cell carcinoma as a prognostic factor

2018 ◽  
Vol 32 (6) ◽  
pp. e236-e237 ◽  
Author(s):  
K.V. Orlova ◽  
V.V. Delektorskaya ◽  
Y.V. Vishnevskaya ◽  
T.T. Kondratieva ◽  
N.F. Orel ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Somatostatin Receptor ◽  
Receptor Type ◽  
Merkel Cell

Quantitation of somatostatin receptor type 2 in neuroendocrine (merkel cell) carcinoma of the skin by competitive RT-PCR

1999 ◽  
Vol 10 (1) ◽  
pp. 37-46 ◽  
Author(s):  
Mauro Papotti ◽  
Luigia Macri’ ◽  
Alberto Pagani ◽  
Filippo Aloi ◽  
Gianni Bussolati
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Somatostatin Receptor ◽  
Receptor Type ◽  
Merkel Cell ◽  
Rt Pcr

scholarly journals Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143)

2021 ◽  
Vol 11 ◽  
Author(s):  
Marco Rastrelli ◽  
Paolo Del Fiore ◽  
Irene Russo ◽  
Jacopo Tartaglia ◽  
Alessandro Dal Monico ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Regional Lymph Node ◽  
Treatment Strategies ◽  
University Hospital ◽  
Merkel Cell ◽  
Pathological Characteristics ◽  
Negative Prognostic Factor

BackgroundMerkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. The incidence of the disease has undergone a significant increase in recent years, which is caused by an increase in the average age of the population and in the use of immunosuppressive therapies. MCC is an aggressive pathology, which metastasizes early to the lymph nodes. These characteristics impose an accurate diagnostic analysis of the regional lymph node district with radiography, clinical examination and sentinel node biopsy. In recent years, there has been a breakthrough in the treatment of the advanced pathology thanks to the introduction of monoclonal antibodies acting on the PD-1/PD-L1 axis. This study aimed to describe the clinico-pathological characteristics, treatment strategies and prognostic factors of MCC.MethodsA retrospective cohort study was conducted involving 143 consecutive patients who were diagnosed and/or treated for MCC. These patients were referred to the Veneto Institute of Oncology IOV-IRCCS and to the University Hospital of Padua (a third-level center) in the period between December 1991 and January 2020. In the majority of cases, diagnosis took place at the IOV. However, some patients were diagnosed elsewhere and subsequently referred to the IOV for a review of the diagnosis or to begin specific therapeutic regimens.Results143 patients, with an average age of 71 years, were affected mainly with autoimmune and neoplastic comorbidities. Our analysis has shown that age, autoimmune comorbidities and the use of therapy with immunomodulating drugs (which include corticosteroids, statins and beta-blockers) are associated with a negative prognosis. In this sense, male sex is also a negative prognostic factor.ConclusionsAutoimmune and neoplastic comorbidities were frequent in the studied population. The use of drugs with immunomodulatory effects was also found to be a common feature of the population under examination. The use of this type of medication is considered a negative prognostic factor. The relevance of a multidisciplinary approach to the patient with MCC is confirmed, with the aim of assessing the risks and benefits related to the use of immunomodulating therapy in the individual patient.

Absolute Lymphocyte Count as a Prognostic Factor for Merkel Cell Carcinoma

2012 ◽  
Vol 84 (3) ◽  
pp. S136-S137
Author(s):  
M.E. Johnson ◽  
A. Turaka ◽  
F. Zhu ◽  
T. Galloway ◽  
J. Farma ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Merkel Cell

Absolute Lymphocyte Count: A Novel Prognostic Factor for Merkel Cell Carcinoma

2013 ◽  
Vol 3 (2) ◽  
pp. S10-S11
Author(s):  
M.E. Johnson ◽  
A. Turaka ◽  
F. Zhu ◽  
T. Galloway ◽  
J. Farma ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Merkel Cell

scholarly journals Intron 4–5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance

2021 ◽  
Author(s):  
Costantino Ricci ◽  
Luca Morandi ◽  
Francesca Ambrosi ◽  
Alberto Righi ◽  
Dino Gibertoni ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Skin Tumor ◽  
Epigenetic Mechanism ◽  
Merkel Cell ◽  
Pathological Features ◽  
Intron 4 ◽  
Overall Mortality

AbstractMerkel cell carcinoma (MCC) is an aggressive skin tumor with neuroendocrine differentiation, mainly affecting elderly population or immunocompromised individuals. As methylation of the human telomerase reverse transcriptase (mhTERT) has been shown to be a prognostic factor in different tumors, we investigated its role in MCC, in particular in intron 4–5 where rs10069690 has been mapped and recognized as a cancer susceptibility locus. DNA methylation analysis of hTERT gene was assessed retrospectively in a cohort of 69 MCC patients from the University of Bologna, University of Turin and University of Insubria. Overall mortality was evaluated with Kaplan-Meier curves and multivariable Royston-Parmar models. High levels of mhTERT (mhTERThigh) (HR = 2.500, p = 0.015) and p63 (HR = 2.659, p = 0.016) were the only two clinico-pathological features significantly associated with a higher overall mortality at the multivariate analysis. We did not find different levels of mhTERT between MCPyV (+) and (−) cases (21 vs 14, p = 0.554); furthermore, mhTERThigh was strongly associated with older age (80.5 vs 72 years, p = 0.026), no angioinvasion (40.7% vs 71.0%, p = 0.015), lower Ki67 (50 vs 70%, p = 0.005), and PD-L1 expressions in both tumor (0 vs 3%, p = 0.021) and immune cells (0 vs 10%, p = 0.002). mhTERT is a frequently involved epigenetic mechanism and a relevant prognostic factor in MCC. In addition, it belongs to the shared oncogenic pathways of MCC (MCPyV and UV-radiations) and it could be crucial, together with other epigenetic and genetic mechanisms as gene amplification, in determining the final levels of hTERT mRNA and telomerase activity in these patients.

Involvement of Felis catus papillomavirus type 2 in the tumorigenesis of feline Merkel cell carcinoma

2021 ◽  
pp. 030098582110454
Author(s):  
Soma Ito ◽  
James K. Chambers ◽  
Ayumi Sumi ◽  
Nanako Yamashita-Kawanishi ◽  
Tetsuo Omachi ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Single Case ◽  
Felis Catus ◽  
Merkel Cell ◽  
Cutaneous Lesions ◽  
Viral Oncogenes ◽  
P53 Immunoreactivity

Merkel cell carcinoma (MCC) is a cutaneous neuroendocrine tumor. We recently demonstrated that cats with MCC often have other proliferative cutaneous lesions, such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Based on this finding, we hypothesize that Felis catus papillomavirus (FcaPV) is involved in the development of MCC in cats, similar to SCC and BCC. To investigate this hypothesis, the presence of FcaPV nucleic acid and immunoreactivity for tumor suppressor proteins were examined in 21 feline MCC cases. Polymerase chain reaction using FcaPV type-specific primers detected FcaPV2 DNA in 20/21 samples of MCC. The complete FcaPV2 sequence was characterized in one case. In situ hybridization for FcaPV2 E7 revealed punctate nuclear signals within tumor cells in 19/21 MCC. Increased immunoreactivity for p16CDKN2A protein and decreased immunoreactivity for retinoblastoma (pRb) and p53 proteins were observed in 20/21 MCC. These results suggest that feline MCC cases are infected with FcaPV2 and the subsequent inhibition of pRb and p53 induced by integrated viral oncogenes is associated with feline MCC tumorigenesis, similar to other PV-induced proliferative cutaneous lesions. On the other hand, the single case of FcaPV2-negative MCC showed strong p53 immunoreactivity, suggesting mutations in p53 caused by cancer inducers other than FcaPV2 infection in this case. The present study suggests FcaPV2 as a cause of feline MCC.

Sign in / Sign up

Export Citation Format

Share Document